FDA Panel To Assess Trial Design As It Reviews Teva's Azilect To Delay Progression Of Parkinson's
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency reviewers identify numerous issues with analyses and results of ADAGIO trial.
You may also be interested in...
Data For Teva's Azilect Not Good Enough For Claim Of Slowing Parkinson's Progression, FDA Panel Says
FDA advisory committee reluctant to set precedent for disease modification indication without strong data.
Data For Teva's Azilect Not Good Enough For Claim Of Slowing Parkinson's Progression, FDA Panel Says
FDA advisory committee reluctant to set precedent for disease modification indication without strong data.
Teva Parkinson's Agent Azilect Will Launch Within 10 Weeks
Partner Eisai will continue to co-develop the MAO-B inhibitor for Alzheimer's disease, but it is "still considering" whether it will opt to co-promote the agent for Parkinson's.